Workflow

Pharmacy Automation: Technologies and Global Markets Report 2024-2028 Featuring Major Players - BD, Baxter, Omnicell, and KUKA - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 3, 2024
Health, Pharmaceutical, RFID, Automation, Omnicell, Drug discovery, Internet of things, KUKA, ESG, Pharmacy, Internet, Artificial intelligence, Pharmacist, Workflow, Cloud computing, Growth, USD, Baxter, Approximation error

The "Pharmacy Automation: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharmacy Automation: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The Global Pharmacy Automation Market was valued at USD 7.8 Billion in 2023, and is expected to reach USD 12.7 Billion by 2028, rising at a CAGR of 10.20%.
  • This report is designed to be a helpful business tool that will provide a thorough evaluation of the global pharmacy automation market.
  • Definitive and detailed estimates and forecasts of the global market are provided, followed by a detailed analysis of segments and regions.

Recent Research Supports Sedation-Free TNE for Effective Management of GI Disorders Utilizing the EvoEndo System

Retrieved on: 
Wednesday, April 3, 2024
Health, Medical Devices, Hospitals, Health Technology, Other Health, General Health, Biotechnology, Safety, Anesthesia, TNE, Evaluation, Patient, Pediatrics, Efficacy, Abstract, Male, Workflow, EGD, Eosinophilic esophagitis, Endoscopy, Esophagogastroduodenoscopy, Nursing

Recently published scientific abstracts and peer-reviewed papers support the efficacy and demand for gastroenterology programs to offer Sedation-Free Transnasal Endoscopy (TNE) utilizing the EvoEndo System as an alternative to traditional TNE.

Key Points: 
  • Recently published scientific abstracts and peer-reviewed papers support the efficacy and demand for gastroenterology programs to offer Sedation-Free Transnasal Endoscopy (TNE) utilizing the EvoEndo System as an alternative to traditional TNE.
  • Findings suggest a valuable opportunity to optimize the patient experience, minimize risks associated with anesthesia, and improve diagnostic outcomes.
  • There were no adverse events, suggesting promising potential for TNE as a diagnostic tool in assessing esophageal disorders.
  • These studies highlight the advantages of offering unsedated TNE and the viability of broader applications in pediatric endoscopy.

ANPD Readies Tomorrow’s Nursing Professional Development Leaders With Wolters Kluwer EBP Workflow Solution

Retrieved on: 
Wednesday, April 3, 2024
Legal, Technology, Nursing, Accounting, Health Technology, Professional Services, Health Insurance, Software, Practice Management, Health, RN, QI, Culture, Mentorship, Public, Wolters Kluwer, Education, EBP, ANPD, Journal, Research, NPD, Acquisition, AI, Senior, Workflow, Quality, Multimedia, Evidence-based practice, Leadership Academy, Human

Wolters Kluwer Health today announced that the Association for Nursing Professional Development (ANPD) has selected Ovid® Synthesis to help support evidence-based practice (EBP), quality improvement (QI), and research for two key programs.

Key Points: 
  • Wolters Kluwer Health today announced that the Association for Nursing Professional Development (ANPD) has selected Ovid® Synthesis to help support evidence-based practice (EBP), quality improvement (QI), and research for two key programs.
  • View the full release here: https://www.businesswire.com/news/home/20240403110031/en/
    The Association for Nursing Professional Development has selected the innovative workflow solution, Ovid® Synthesis, to help support evidence-based practice, quality improvement for their Nursing Professional Development Leadership Academy and the Evidence-Based Practice Academy.
  • (Photo: Business Wire)
    “ANPD and Wolters Kluwer share a vision for developing healthcare leaders and practitioners that make a real impact on patient lives.
  • “We look forward to jumpstarting our year-long academies with Ovid Synthesis at this year’s ANPD Aspire Convention .”
    For the past 30 years, the Association for Nursing Professional Development (ANPD) has advanced the specialty practice of nursing professional development for the enhancement of healthcare outcomes by providing access to education, experience, and resources targeting the various needs of nursing professional development team members.

PaceMate Hits 100,000th Patient Transmission Milestone with Cutting-Edge Ambulatory Remote Monitoring Platform

Retrieved on: 
Tuesday, April 2, 2024
Cardiology, Software, Biometrics, Health, Medical Devices, Data Management, Health Technology, Technology, Trust, FACC, Patient, Workflow, Internet, Algorithm, Entrepreneurship, Nursing

PaceMate®, a market-leading cardiac remote monitoring and cardiac data management platform , announced today the completion of its 100,000th ambulatory patient transmission managed through PaceMateLIVE™.

Key Points: 
  • PaceMate®, a market-leading cardiac remote monitoring and cardiac data management platform , announced today the completion of its 100,000th ambulatory patient transmission managed through PaceMateLIVE™.
  • PaceMate leverages advanced algorithms to deliver the only end-to-end solution, merging the entire workflow – from ordering to billing – into a singular, efficient experience.
  • PaceMate is the universal solution for cardiac data management across the disease spectrum," said Tripp Higgins, CEO and Co-Founder of PaceMate.
  • PaceMate provides clinicians the flexibility to choose from the top five ambulatory monitoring manufacturers with one single integration for a tailored healthcare solution.

Availity Launches Groundbreaking AI Claims Denial Prediction Tool, Powered by Anomaly Insights

Retrieved on: 
Tuesday, April 2, 2024
Data Management, Technology, Professional Services, Health, Payments, Health Technology, Apps, Applications, Software, Artificial Intelligence, Networks, Insurance, Database, Artificiality, Partnership, Artificial intelligence, AI, Workflow, Pharmacy, API, Product management, Medical device

Predictive Editing’s engine, powered by artificial intelligence (AI), helps prevent claims denials by analyzing extensive claims data to identify potential denials prior to submission at the front-end of the provider’s submission workflow, allowing for timely corrections and smoother adjudication.

Key Points: 
  • Predictive Editing’s engine, powered by artificial intelligence (AI), helps prevent claims denials by analyzing extensive claims data to identify potential denials prior to submission at the front-end of the provider’s submission workflow, allowing for timely corrections and smoother adjudication.
  • In a recent proof-of-concept study of more than 100 million claims from two large health systems, the Predictive Editing tool demonstrated impressive results, flagging more than $828 million denials with 97% precision.
  • The Predictive Editing tool analyzes millions of historical claims, comparing them to remittance data to detect payment patterns.
  • “Our partnership with Availity provides a unique opportunity to bring advanced AI/ML capabilities directly to providers and payers to eliminate cost and waste.”

Docyt to Unveil New Voice-Based Transaction Categorization for Its AI-Powered Accounting Automation Platform at AAHOACON24

Retrieved on: 
Tuesday, April 2, 2024
Technology, Accounting, Professional Services, Small Business, Data Analytics, Lodging, Travel, Apps, Applications, Software, Audio, Video, Internet, Mobile, Wireless, Data Management, Finance, Venture Capital, Fintech, Artificial Intelligence, Automation, ROI, Algorithm, Face, News, AI, Workflow, Account, Book, Multimedia, Sales

Docyt , the frontrunner in AI-driven accounting automation technology, will unveil new voice-based transaction categorization functionality at AAHOACON24.

Key Points: 
  • Docyt , the frontrunner in AI-driven accounting automation technology, will unveil new voice-based transaction categorization functionality at AAHOACON24.
  • Docyt will demonstrate this and other new features of its AI-powered real-time accounting platform at this year’s show in booth #1625.
  • View the full release here: https://www.businesswire.com/news/home/20240402181777/en/
    Docyt's new voice-based transaction categorization for its AI-powered accounting automation platform enables business stakeholders to review uncategorized transactions in the Docyt mobile app and simply leave voice notes which are transcribed by Docyt’s AI to complete the categorization process.
  • Visit www.docyt.com to learn more about the company’s AI-driven accounting automation platform, and follow Docyt on LinkedIn to stay up to date on the company’s latest news.

Kardium Announces Completion of Paroxysmal Enrollment in the PULSAR IDE Study

Retrieved on: 
Tuesday, April 2, 2024
Software, Hardware, Medical Devices, Technology, Health Technology, Clinical Trials, Surgery, Nanotechnology, Cardiology, Biotechnology, FDA, Health, Inc., Atrial fibrillation, Patient, Gold, PFA, McGill University Health Centre, IDE, Electrode, Workflow, Heart, PMA, Safety, Patient safety, Multimedia, Mount Sinai Hospital, Food, Medical device

Kardium Inc. , a private medical device company that has developed the Globe® System for the treatment of atrial fibrillation (AF) using pulsed field ablation (PFA), announced today the successful completion of enrollment in the paroxysmal cohort of the pivotal PULSAR IDE (Investigational Device Exemption) study.

Key Points: 
  • Kardium Inc. , a private medical device company that has developed the Globe® System for the treatment of atrial fibrillation (AF) using pulsed field ablation (PFA), announced today the successful completion of enrollment in the paroxysmal cohort of the pivotal PULSAR IDE (Investigational Device Exemption) study.
  • (Photo: Business Wire)
    The PULSAR IDE study, an international, multi-center clinical trial, is designed to evaluate the safety and effectiveness of the Globe System for the treatment of atrial fibrillation.
  • The successful completion of enrollment underscores the commitment of the clinical sites, investigators, and the entire Kardium team.
  • "The completion of enrollment in the PULSAR study represents a major accomplishment for Kardium.

GE HealthCare closes MIM Software acquisition, bolstering its portfolio and advancing its precision care strategy

Retrieved on: 
Monday, April 1, 2024
Technology, Health, Other Health, Radiology, Oncology, Other Technology, Practice Management, Medical Devices, Software, Managed Care, General Health, Health Technology, Hardware, Data Management, Neurology, Automation, Diagnosis, Cardiology, Molecular imaging, American Urological Association, MRI, Prostate cancer, Nuclear medicine, SNMMI, Patient, PET, Radiation, Cancer, Society, Adjustment, Radiation therapy, Workflow, Radiopharmaceutical, GE HealthCare, SPECT, MIM, Brachytherapy, ASCO, European Association of Urology, Hand, Medical imaging

The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states.

Key Points: 
  • The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states.
  • "We are thrilled to welcome MIM Software, known for driving innovation in multimodal image analytics and workflow, to our global GE HealthCare team,” said Peter Arduini, President & CEO, GE HealthCare.
  • “These new capabilities align with our precision care strategy to personalize care, enhance hospital efficiency and clinician effectiveness, and appeal to new and existing GE HealthCare and MIM Software users who see this as an opportunity to better serve patients and help improve outcomes."
  • “Today marks an exciting new chapter for our team and technology,” adds Andy Nelson, CEO, MIM Software at GE HealthCare.

Domo Announces Enhanced Data Solutions with App Studio and Unveils the Power of BI and Automation Capabilities with Workflows

Retrieved on: 
Friday, March 29, 2024
Apps, Applications, Technology, Mobile, Wireless, Software, Networks, Internet, Hardware, Data Management, Artificial Intelligence, Constellation, Automation, App, Conference, Software as a service, Workflow, SVP, AI, IOS, Work, JavaScript, Mobile phone

Today Domo (Nasdaq: DOMO) announced at Domopalooza: the AI + Data Conference that App Studio, Domo’s low-code app builder, is now generally available.

Key Points: 
  • Today Domo (Nasdaq: DOMO) announced at Domopalooza: the AI + Data Conference that App Studio, Domo’s low-code app builder, is now generally available.
  • The company also announced that it has bolstered its low-code automation engine Workflows, streamlining and extending automation with third-party actions.
  • Every element, component and visualization is meticulously aligned with diverse themes, ensuring users achieve consistency across all app pages effortlessly.
  • With App Studio, customers have a seamless native experience right from the start, eliminating the need for any coding.

BioSkryb Genomics to Present Novel Research on Tumor Heterogeneity at American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Thursday, March 28, 2024
Oncology, Health, Health Technology, Genetics, Research, Science, Biotechnology, Single-cell analysis, Disease, Transcriptome, Malignancy, Neoplasm, DNA, Genome, Workflow, AACR, Doctor of Philosophy, Phenotype, Genomics, SNV, Ageing, CNV, Mobile phone

BioSkryb Genomics , a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer Research® (AACR) Annual Meeting 2024 on April 5-10, 2024 in San Diego, CA.

Key Points: 
  • BioSkryb Genomics , a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer Research® (AACR) Annual Meeting 2024 on April 5-10, 2024 in San Diego, CA.
  • “Tumor heterogeneity is a key challenge for researchers in the cancer research field.
  • As tumors evolve, subclones emerge with mutations that convey adaptive phenotypes, including resistance to therapies,” said Suresh Pisharody, CEO of BioSkryb.
  • “Our next generation single-cell technology gives scientists the tools to better understand the way tumors evolve with a comprehensive, scalable, and streamlined workflow.